sci天天读
可切除I-III期非小细胞肺癌患者EGFR突变率：EARLY-EGFR研究结果
SCI10 July 2024Prevalence of EGFR Mutations in Patients With Resected Stage I-III NSCLC: Results From the EARLY-EGFR Study
具有EGFR种系突变肺腺癌的突变特征和临床结果
SCI9 July 2024Mutational characteristics and clinical outcomes for lung adenocarcinoma with EGFR germline mutations
局晚期肺癌调强放疗的长期前瞻性结果-随机临床试验的二次分析
SCI8 July 2024Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer
循环肿瘤DNA引导靶向治疗晚期非小细胞肺癌：一项非随机临床试验
SCI7 July 2024Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer: A Nonrandomized Clinical Trial
肿瘤免疫抑制的昼夜节律控制影响免疫检查点阻断剂的疗效
SCI5 July 2024Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade
抗肿瘤祖细胞耗尽的CD8+ T细胞通过TCR参与维持
SCI4 July 2024Antitumor progenitor exhausted CD8+ T cells are sustained by TCR engagement
Selpercatinib对一线RET融合阳性的进展期非小细胞肺癌的中枢神经系统保护作用
SCI3 July 2024CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non–Small Cell Lung Cancer
Telisotuzumab Vedotin单药治疗先前治疗过的c-Met蛋白过度表达晚期非鳞状EGFR野生型NSCLC的2期试验
SCI2 July 2024Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Non-Squamous EGFR-Wildtype NSCLC in the Phase 2 LUMINOSITY Trial
肿瘤学中的双特异性和多特异性抗体：机遇与挑战
SCI1 July 2024Bispecific and multispecific antibodies in oncology: opportunities and challenges
肿瘤学中实现公平的人工智能
SCI30 June 2024Towards equitable AI in oncology
Amivantamab联合Lazertinib治疗未治疗的EGFR基因突变晚期非小细胞肺癌
SCI29 June 2024Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
癌症RNA疫苗：实践原则
SCI28 June 2024RNA vaccines for cancer: Principles to practice
利用细菌进行癌症免疫治疗
SCI27 June 2024Exploiting bacteria for cancer immunotherapy
经治晚期或转移性非小细胞肺癌应用Sacituzumab Govitecan对比多西他赛：随机III期EVOKE-01研究
SCI26 June 2024Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study
心肺适能蛋白质组学分析用于预测死亡率和多系统疾病风险
SCI25 June 2024Proteomic analysis of cardiorespiratory fitness for prediction of mortality and multisystem disease risks
驱动KRAS-突变癌症的ERK调节磷酸蛋白质组的测定
SCI24 June 2024Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer
定义KRAS突变癌症中的KRAS和ERK依赖性转录组
SCI23 June 2024Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
精准肿瘤学中组织非特异性治疗的发展趋势
SCI22 June 2024The evolving landscape of tissue-agnostic therapies in precision oncology
Ivonescimab联合化疗用于EGFR变异的NSCLC：一项随机临床试验
SCI21 June 2024Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
618Taletrectinib治疗中国ROS1+非小细胞肺癌患者的疗效和安全性:II期TRUST-I研究
SCI20 June 2024Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study